Shefali Shah is Global Vice President, Market Value and Commercial Effectiveness at MindMaze, where she is responsible for developing the global market access and reimbursement strategy. With 20 years of experience in Life Sciences, Shefali has been instrumental in launching several blockbuster products and growing in-market products for companies like Novo Nordisk, GSK and others. Shefali brings a wide range of expertise in optimizing commercial execution based on her experience in leading and aligning Medical, Market Access, Insights and Brand Teams. Additionally, Shefali combines her passion for science and evidence-based data with her experience with ancient wisdom traditions like yoga and meditation to advance health and wellness. Shefali earned a BS in Electrical Engineering from Columbia University in the City of New York and an MBA from NYU Stern School of Business, and is a RYS Certified Yoga Instructor.
Dustin Carver was the former Head, US Market Access at MindMaze, supporting US go-to-market strategy and market access strategy development, and is now Senior Director, Market Access and Payer Strategy, at Recordati Rare Diseases. Prior to joining MindMaze, Dustin had 17 years of experience across a variety of roles in the pharmaceutical industry, in areas such as product support, sourcing, portfolio management, and market intelligence. Most recently, Dustin led innovation initiatives and value-based contracting with payers and PBMs at Novo Nordisk. Dustin earned a BS in Biotechnology and an MBA in Finance and Entrepreneurship from Rutgers University and an MSJ in Intellectual Property from Seton Hall University.
Demand is increasing, yet many payers are still hesitant to cover them – in large part thanks to laws that govern coverage, a lack of clarity regarding coverage approaches, and questions regarding evidence generation for these solutions.